Reo13 Brain – Post-Trial Sample Analysis
Research type
Research Study
Full title
Reo13 Brain – Post-Trial Sample Analysis, Version 1.0
IRAS ID
235809
Contact name
Adel Samson
Contact email
Sponsor organisation
University of Leeds
Duration of Study in the UK
5 years, months, days
Research summary
The aim of this post-trial sample analysis study is to explore further scientific questions using the brain tissue and peripheral blood samples from the now closed Reo13 Brain trial (full title: A clinical study to evaluate the biological effects of preoperative intravenous administration of wild-type reovirus (REOLYSIN®) in patients prior to surgical resection of recurrent high grade primary or metastatic brain tumours; REC ref 12/YH/0402). \n\nIn the previous Reo13 Brain study, brain tumour samples and peripheral bloods cells (also known as immune or white blood cells) were taken from research participants. Brain tumour tissue samples were taken at surgery. Peripheral blood samples were taken at visits in which participants received REOLYSIN treatment. \n\nSamples from this previous Reo13 Brain study were analysed for presence of reovirus. This post-trial sample analysis study aims to look at the replication of reovirus in tumour tissue, the effects of reovirus on the tumour immune microenvironment, and the upregulation of immune and apoptosis-related genes in tumour tissue. \n\nIn the previous Reo13 Brain study, the peripheral blood samples were analysed for the presence of anti-reovirus neutralising antibodies and activation of various immune cell subsets. This post-clinical study aims to to look at upregulation of immune checkpoint proteins, the presence of reovirus genome replication in immune cells and reovirus-related immune-mediated anti-cancer effects.
REC name
London - Bloomsbury Research Ethics Committee
REC reference
18/LO/0080
Date of REC Opinion
23 Jan 2018
REC opinion
Favourable Opinion